Epigenomics Takes Its First Solo Step In Development of Oncotype Dx Rival | GenomeWeb

This week, Epigenomics said it had validated two prognostic markers for a breast-cancer diagnostic that could compete with Genomic Health's Oncotype Dx, but was abandoned by former partner Roche Diagnostics, the company said this week.

The study examined the use of Epigenomics' main DNA methylation biomarker, PITX2, as well as a secondary marker, to predict breast cancer recurrence in 395 patients with estrogen receptor-positive, node-positive cancer who had been treated with the chemotherapeutic anthracycline as adjuvant therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.